LB PharmaceuticalsLB PharmaceuticalsLB Pharmaceuticals
  • Our Company
    • About Us
    • Leadership
    • Scientific Advisory Board
    • Contact Us
  • Pipeline
  • Clinical Programs
  • Investors
    • About Schizophrenia
    • How do antipsychotics work?
    • Publications
    • News
    • Presentations
    • SEC Filings

News


LB Pharmaceuticals Press Releases

September 25, 2020LB Pharmaceuticals Inc Secures $10.0 million in Additional Financing
September 14, 2020LB Pharmaceuticals Inc Announces Results of LB-102 First-in-Human Clinical Study
September 2, 2020LB Pharmaceuticals Inc Announces the Hiring of Dr. Anna Eramo as Chief Medical Officer
January 22, 2020 LB Pharmaceuticals Inc Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia
August 15, 2019 LB Pharmaceuticals Inc Announces the Publication of Its First Peer-Reviewed Manuscript
July 8, 2019LB Pharmaceuticals Inc Appoints Robert R. Ruffolo, Jr., Ph.D. to its Board of Directors
March 4, 2019 LB Pharmaceuticals Inc  Secures $8.4 Million in Series A Financing
January 1, 2019LB Pharmaceuticals Inc Announces Issuance of U.S. Patent Covering N-Methyl Amisulpride for the Treatment of Psychiatric Disorders

Want to stay in the loop?

Join our mailing list


All Rights Reserved.

Pipeline

LB-102

About

Company

Contact

Write Us

© 2021 LB Pharmaceuticals. , a development stage life sciences company whose lead compound, LB-102, is a proprietary, patented version of amisulpride.

  • Our Company
    • About Us
    • Leadership
    • Scientific Advisory Board
    • Contact Us
  • Pipeline
  • Clinical Programs
  • Investors
    • About Schizophrenia
    • How do antipsychotics work?
    • Publications
    • News
    • Presentations
    • SEC Filings